Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: carbohydrate-based vaccines - Ancora

Drug Profile

Research programme: carbohydrate-based vaccines - Ancora

Latest Information Update: 30 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ancora Pharmaceuticals
  • Class Carbohydrates; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malaria; Staphylococcal infections

Most Recent Events

  • 07 Dec 2010 Ancora Pharmaceuticals receives federal grant from US Government under the Qualifying Therapeutic Discovery Program for vaccine development in Malaria (prevention)
  • 07 Dec 2010 Preclinical trials in Staphylococcal infections (Prevention) in USA (unspecified route)
  • 27 Oct 2005 Ancora Pharmaceuticals receives SBIR grant from the National Institutes of Health for development of malaria vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top